<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article328</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/INPULSIS_Trials" style="display:block; margin-bottom:10px;">INPULSIS Trials Original</a></li>
<h2><strong>INPULSIS Trials</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Nintedanib for Idiopathic Pulmonary Fibrosis". The New England Journal of Medicine. 2014. 370(22):2071-2082. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
<br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcomes<br/>
8.2 Secondary Outcome<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does nintedanib, a multiple tyrosine kinase inhibitor, slow the progression of idiopathic pulmonary fibrosis?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Nintedanib reduced the annual rate of decline in forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Idiopathic pulmonary fibrosis is a chronic, progressive lung disease with limited treatment options, characterized by a decline in lung function and quality of life. The INPULSIS trials were two replicate phase 3 studies that demonstrated that nintedanib significantly reduced the rate of decline in FVC over a 52-week treatment period in patients with idiopathic pulmonary fibrosis, suggesting a slowing of disease progression.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the latest updates, these trials have contributed to nintedanib being included in clinical guidelines as a treatment option for idiopathic pulmonary fibrosis.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Two replicate 52-week, randomized, double-blind, placebo-controlled phase 3 trials (INPULSIS-1 and INPULSIS-2).<br/>
- N=1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo.<br/>
- Intervention: 150 mg of nintedanib twice daily.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Participants were 40 years or older with a diagnosis of idiopathic pulmonary fibrosis within the last 5 years.<br/>
- Patients required an FVC of ≥50% and a diffusion capacity of the lungs for carbon monoxide (DLCO) of 30-79%.<br/>
- High-resolution computed tomography (HRCT) was performed within 12 months prior to trial.<br/>
<br/>
Inclusion Criteria<br/>
- Age ≥40 years<br/>
- Diagnosis of idiopathic pulmonary fibrosis within previous 5 years<br/>
- FVC ≥50% of predicted value<br/>
- DLCO 30-79% of the predicted value<br/>
<br/>
Exclusion Criteria<br/>
- Prednisone &gt;15 mg/day (or equivalent)<br/>
- Investigational treatments for idiopathic pulmonary fibrosis<br/>
- Recent surgical lung biopsy incompatible with idiopathic pulmonary fibrosis<br/>
<br/>
Baseline Characteristics<br/>
- Similar across intervention and placebo groups in each trial.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Nintedanib 150 mg twice daily or placebo for 52 weeks.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes<br/>
- Adjusted annual rate of decline in FVC <br/>
  INPULSIS-1: −114.7 ml (nintedanib) vs. −239.9 ml (placebo); difference: 125.3 ml, P&lt;0.001<br/>
  INPULSIS-2: −113.6 ml (nintedanib) vs. −207.3 ml (placebo); difference: 93.7 ml, P&lt;0.001<br/>
<br/>
Secondary Outcome<br/>
- Time to first acute exacerbation<br/>
  INPULSIS-1: No significant difference (HR 1.15; P=0.67)<br/>
  INPULSIS-2: Significant benefit (HR 0.38; P=0.005)<br/>
- Change from baseline in SGRQ score<br/>
  INPULSIS-1 and INPULSIS-2: Inconsistent significant differences<br/>
- Diarrhea was the most common adverse event associated with nintedanib.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Not applicable for the summary format.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Funded by Boehringer Ingelheim.<br/>
- Some authors reported receiving various fees from pharmaceutical companies.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- The article link provided in the reference leads to the full text article and supplementary materials.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
